Pulmovant

Developing inhaled therapies for patients with pulmonary diseases, starting with pulmonary hypertension associated

+ Add to sales board

Highlights

  • New on EvolcAdded 2026-11-14

About Pulmovant

Pulmovant develops therapies for pulmonary diseases. Its first investigational product is mosliciguat, an inhaled treatment in development for pulmonary hypertension associated with interstitial lung disease.

The company was founded in 2023 and is part of the Roivant family of companies. Its open roles cover clinical development, regulatory affairs, CMC, biostatistics and related functions.

Product: Mosliciguat, an investigational inhaled therapy for pulmonary hypertension associated with interstitial lung disease.

Jobs at Pulmovant

No open positions listed right now.

More biotech & pharma companies

  • Ratiotx

    Develops targeted radiopharmaceuticals for treating cancer, from discovery through early clinical trials
    United StatesBiotech & pharma
    New on Evolc
  • ReCode Therapeutics

    Develops mRNA and gene-correction medicines for people with genetically defined diseases, including cystic fibrosis
    United StatesBiotech & pharma
    New on Evolc
  • Recursion

    AI-enabled drug discovery and development for pharmaceutical partners and patients with oncology and rare diseases
    United StatesBiotech & pharma1 open job
    Remote-friendlySalary transparent
  • Remix Therapeutics

    Clinical-stage biotech developing small-molecule mRNA degraders for solid tumors and blood cancers
    United StatesBiotech & pharma
    New on Evolc
  • Replimune

    Develops oncolytic immunotherapies for patients with cancer, including advanced melanoma
    United StatesBiotech & pharma15 open jobs
  • Resilience

    Biologics and sterile drug product CDMO for biotech and pharma companies, from clinical batches to commercial supply
    United StatesBiotech & pharma
    New on Evolc

All biotech & pharma companies →

Website technologies

Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.

Content delivery

Content management

  • DrupalHigh confidence
    First detected
    Last detected
    Last checked
    Detection evidence

Frontend frameworks

  • jQueryHigh confidence
    First detected
    Last detected
    Last checked
    Detection evidence
  • Tailwind CSSMedium confidence
    First detected
    Last detected
    Last checked
    Detection evidence

Hosting

Recruiting

  • GreenhouseMedium confidence
    First detected
    Last detected
    Last checked
    Detection evidence

Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.